Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING NA

A Phase 4 Clinical Study to Investigate the Effectiveness and Safety of Skin Resurfacing

NCT07214272 · View on ClinicalTrials.gov ↗

Study Summary

This study is a prospective, post-marketing (Phase 4) non-registrational single-arm, open-label, multicenter study.

Conditions Studied

Interventions

  • DEVICE Fraxel® FTX Laser System

Study Locations (5)

California

  • Dermatology Cosmetic Laser Associates of La Jolla, Inc. d/b/a West Dermatology Research Center — La Jolla

Florida

  • Miami Dermatology & Laser Research LLC — Miami

Illinois

  • Oak Dermatology, LLC — Naperville

New York

  • Union Square Laser Dermatology, P.C — New York

Texas

  • Dermatology and Laser Surgery Center — Houston

Trial Details

FieldValue
Enrollment Target 49 participants
Start Date 2025-10-17
Est. Completion 2026-09
Phase NA

Sponsor

Bausch Health Americas

55 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07214272

The ClinicalTrials.gov registry entry for NCT07214272 describes a study currently listed as active not recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 55 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Skin Resurfacing appearing as the primary indexed condition, and to 1 intervention — of which Fraxel® FTX Laser System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT07214272 reports 5 study locations spanning 5 distinct geographic areas — top geographies include California, Florida, Illinois. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT07214272 about?

NCT07214272 is a clinical study titled "A Phase 4 Clinical Study to Investigate the Effectiveness and Safety of Skin Resurfacing". This study is a prospective, post-marketing (Phase 4) non-registrational single-arm, open-label, multicenter study.

What is the current status of trial NCT07214272?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 49 participants. The study started on 2025-10-17. Estimated completion is 2026-09.

What conditions does trial NCT07214272 study?

This clinical trial studies the following conditions: Skin Resurfacing. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT07214272?

The interventions under investigation include: Fraxel® FTX Laser System (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT07214272?

This trial is sponsored by Bausch Health Americas, which has 55 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT07214272 being conducted?

This trial has 5 study locations across California, Florida, Illinois, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial